



## **aTyr Pharma to Present at the Jefferies London Healthcare Conference**

October 25, 2022

SAN DIEGO, Oct. 25, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present a corporate overview at the Jefferies London Healthcare Conference, which is scheduled to take place November 15 – 17, 2022, in London, U.K.

Details of the presentation appear below:

Conference: Jefferies London Healthcare Conference

Date: Tuesday, November 15, 2022

Time: 3:15pm GMT / 10:15am EST

Location: London, U.K.

In addition to the presentation, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the conference. An audio webcast of the event will be available on the Investor's section of the company's website at [www.atyrpharma.com](http://www.atyrpharma.com). Following the event, a replay of the presentation will be available on the aTyr website for at least 90 days.

### **About aTyr**

aTyr is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. aTyr's research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr's primary focus is efzofitimid, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to downregulate immune engagement in fibrotic lung disease. For more information, please visit <http://www.atyrpharma.com>.

### **IMMEDIATE RELEASE**

#### **Contact:**

Ashlee Dunston

Director, Investor Relations and Corporate Communications

[adunston@atyrpharma.com](mailto:adunston@atyrpharma.com)

Source: aTyr Pharma, Inc.